Global law firm Ashurst has advised British Patient Capital on its investment as part of Epilepsy GTX's $33 million Series A Funding Round.
Epilepsy GTX is a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy.
The Ashurst team was led by corporate partner Jacob Gold and senior associate Dillon Fuzi, with support from associate Elnaz Cadogan.
Ashurst has advised British Patient Capital on a number of investments in growth business in the UK life sciences sector over recent years, including its participation in funding rounds for Purespring Therapeutics, Phagenesis and Epsilogen, among others.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).
